Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Levemir is a long-acting insulin that’s used to control high blood sugar levels in adults and children with type 1 and type 2 diabetes. There are alternative insulins that could replace Levemir ...

The first insulins varied greatly in purity and strength. Manufacturers improved purification techniques, introduced standardized strengths and developed new long-acting insulins. Although not ...

By type of insulin, the long-acting insulin analogs segment accounted for the highest revenue-grossing segment in the global ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

In the meantime, Novo Nordisk has responded to the threat from the cut-price fast and long-acting insulins with newer insulins that aim to improve on the performance of the established rivals.

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.

Managing diabetes has come a long way, thanks to advancements in treatments and technologies that make life easier and ...

a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.